NEW YORK, NY / ACCESS Newswire / July 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ:RARE) concerning possible violations of federal securities laws.

On July 9, 2025, Ultragenyx issued a press release announcing the randomized controlled portion of the Phase 3 Orbit Study for Osteogenesis Imperfecta is progressing toward final analysts for end of year but stopped short of presenting any interim results. Ultragenyx had "hoped to be able to stop the study early" if positive results were achieved at the interim analysis.

Following this news, Ultragenyx's stock price fell by $10.83 per share to open at $30.61 per share.
To obtain additional information, go to:

https://zlk.com/pslra-1/ultragenyx-pharmaceutical-inc-lawsuit-submission-form?prid=156548&wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire